OHSU

Kim-Hien T. Dao, D.O., Ph.D.

Head Shot of Kim-Hien Dao
Specialty:
Cancer
Special Interests:
Bone Marrow Transplant, Hematologic Malignancies
Accepting Patients:
Yes
Languages:
English, Vietnamese (some)

Biography

Dr. Kim-Hien Dao received her post-doctoral internal medicine training at Scripps Mercy Hospital in San Diego, California, and hematology/oncology fellowship training at the University of California, San Diego.  Dr. Dao started her position as an assistant professor in the Division of Hematology & Oncology, Center for Hematologic Malignancies, at OHSU in the fall of 2009. She is a member of the OHSU Knight Cancer Institute. She sees patients who have damage to the blood-forming cells in their bone marrow (myelodysplastic syndrome) or myelodysplastic syndrome that has transformed into acute myelogenous leukemia. She works with other scientists on several clinical trials (research studies), and plans to start her own clinical trials of new treatments for patients with myelodysplastic syndromes that are very likely to become leukemia.  She spends much of her day in the laboratory, studying how blood diseases become leukemia. Dr. Dao hopes her research will help develop treatments to stop the development of leukemia.

Professional Education

  • Degrees:
    DO, Michigan State University, East Lansing, MI, 2003
    B.S., Michigan State University, East Lansing, MI, 2002
    Ph.D., Michigan State University, 2002
  • Residency:
    Internal Medicine, Scripps Mercy Hospital, 2006
  • Fellowship:
    Hematology/Oncology, University of California, San Diego, 2009
  • Certification:
    American Board of Internal Medicine (Internal Medicine), 2006 American Board of Internal Medicine (Hematology), 2009 American Board of Internal Medicine (Oncology), pending
 

OHSU Knight Cancer Institute

Visit our site

Provider Referral Line

503 494-5058

I see patients at:

Multnomah Pavilion

Insurance Information

OHSU accepts most insurance plans

Insurance Information

Clinical Trials

The following clinical trials are currently accepting new participants:

Prospective Evaluation of ruxolitinib Efficacy for CNL/aCML Patients with Mutation of CS3FR

Search all studies